Canadian court supports Excedrin headache superiority claims over Tylenol.
This article was originally published in The Tan Sheet
Executive Summary
EXCEDRIN HEADACHE SUPERIORITY AD CLAIMS OVER TYLENOL are supported in a recent decision by the Ontario Court of Justice in Toronto. On July 25, Judge Donald Taliano denied a McNeil Consumer Products motion for an interlocutory injunction restraining Bristol-Myers Squibb from making statements and distributing ads that claim Excedrin is superior to Tylenol for headache or other pain relief because it contains caffeine.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning